Navigation Links
Aware, Inc. Announces Q1 '09 Earnings Conference Call
Date:4/23/2009

BEDFORD, Mass., April 21 /PRNewswire-FirstCall/ -- Aware, Inc. (Nasdaq: AWRE), a leading supplier of broadband technology and biometrics software, has scheduled a conference call to discuss the company's operating results for the first quarter 2009 on Tuesday, May 5, 2009, at 5:00 p.m. Eastern Time. CEO Michael Tzannes and CFO Rick Moberg will host the earnings conference call.

This call is being webcast by Thomson and can be accessed on the Investor Relations page of our website at www.aware.com/ir. The conference call may also be heard by calling 719-325-4808 at least 10 minutes prior to the call start time. Please reference the confirmation number 1841428.

The webcast is also being distributed through the Thomson StreetEvents Network. Individual investors can listen to the call at www.earnings.com, Thomson's individual investor portal, powered by StreetEvents. Institutional investors can access the call via Thomson StreetEvents (www.streetevents.com), a password-protected event management site.

About Aware

Aware is a leading technology and software supplier for the telecommunications and biometrics industries. For more than ten years, Aware has pioneered innovations at telecommunications standards-setting organizations and continues to develop and market DSL silicon intellectual property and test and diagnostics products. Its StratiPHY(TM) IP product line supports DSL standards, including ADSL2+ and VDSL2, and has been broadly licensed to leading semiconductor companies. Telecom equipment vendors and phone companies use Aware's DSL test and diagnostics modules and Dr. DSL(R) software to help provision DSL c
'/>"/>

SOURCE Aware, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology news :

1. Aware, Inc. Introduces Biometrics Software for Tenprint Autocapture
2. Aware, Inc. Announces Richard Moberg to Return as CFO
3. Aware, Inc. Reports Fourth Quarter and 2007 Financial Results
4. Sun Microsystems and Aware, Inc. Announce Integration of Awares BioSP with Sun Identity Management Solutions
5. Aware, Inc. Reports Fourth Quarter and 2008 Financial Results
6. Aware, Inc. Commences Dutch Auction Tender Offer
7. Aware, Inc. Commences Dutch Auction Tender Offer
8. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
9. Aware, Inc. Announces Preliminary Results of Dutch Auction Tender Offer
10. Aware, Inc. Amends and Extends Dutch Auction Tender Offer
11. Selexis Announces Advanced Approach to Maximize Power of Genetic Elements for Rapid Development of High Performance Cell Lines
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2010)... Miami have analyzed images based on Synthetic Aperture ... Haiti,s earthquake, on January 12. The images reveal ... using data from Japan,s ALOS satellite and made ... of the European Space Agency (ESA) and GEO, ... of countries that promotes the exchange of satellite ...
(Date:2/9/2010)... People with anorexia nervosa, paradoxically, have strikingly high levels ... Children,s Hospital Boston. Their findings, based on MRI imaging ... 20 healthy girls of the same age, appear in ... and Mineral Research . , "It,s counter-intuitive that an ... be storing fat in her marrow," says endocrinologist Catherine ...
(Date:2/9/2010)... The Scripps Research Institute have discovered a potential new ... for sheep and cattle infected with liver fluke. The ... in combating river blindness, a tropical disease that is ... humans. , The study is scheduled for publication ... Proceedings of the National Academy of Sciences ...
Breaking Biology News(10 mins):New international satellite observations help assess future earthquake risk in Haiti 2Anorexics found to have excess fat-- in their bone marrow 2Scripps research team reveals how an old drug could have a new use for treating river blindness 2Scripps research team reveals how an old drug could have a new use for treating river blindness 3Scripps research team reveals how an old drug could have a new use for treating river blindness 4GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 1GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 2GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 3GetWellNetwork Introduces Discharge Planning Tools in Latest Version of PatientLife System 51786 4New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 1New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 2New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 3New Five Question Test Helps Assess Asthma Control in Children Under Five Years of Age 51784 4Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 1Demand for Short Term Medical Help Leads to Growth for Travel Nursing Staffing Agency 3B Prompts Move to New Location and Addition of New Online Tools 51782 2
... prevent global warming, researchers and policymakers are exploring a ... carbon dioxide that reaches the atmosphere. One possible approach ... the source an electric power plant, for example ... theoretically promising, the technique has never been tested in ...
... or array that can quickly detect disorders such as Down ... effective tool in prenatal diagnosis in a series of 300 ... report that appears in the current issue of the journal ... led by Dr. Arthur Beaudet and Dr. Sau Wai Cheung ...
... properties of cancer cells are their ability to divide without ... establish new tumor sites. Now, researchers from the Mayo ... acts as a deadly master switch, both freeing cancer cells ... is potentially good news, say the researchers, who published their ...
Other Biology News:MIT: Safe storage of greenhouse-gas carbon dioxide 2Microarray analysis improves prenatal diagnosis 2Microarray analysis improves prenatal diagnosis 3Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 2Mayo researchers identify dangerous 'two-faced' protein crucial to breast cancer spread and growth 3
(Date:2/9/2010)... 9 Ardea Biosciences, Inc. (Nasdaq: ... , Ph.D., has been appointed to the Company,s Board ... Baker Bros. Advisors, LLC, the manager and advisor to ... ,, "Ardea,s impressive accomplishments have made it an ... to join the Board of Directors," commented Dr. Baker. ...
(Date:2/9/2010)... A leading clinical research center in ... study an investigational drug designed as a possible treatment ... affects between 45 and 90 percent of women of ... not life threatening, dysmenorrhea can be debilitating and psychologically ... absenteeism from work and school. ,, Current therapies for ...
(Date:2/9/2010)... Md. , Feb. 9 ... today that it will release its fourth quarter ... on Tuesday, February 16, 2010 . ,, ... Tuesday, February 16, 2010 , at ... accessible by dialing 1-888-695-0608, with international callers dialing ...
(Date:2/9/2010)... Feb. 9 The American Psychiatric ... sole medical education partner to prepare and manage ... meeting in New Orleans, Louisiana , from ... Enterprise will manage all elements of industry-supported symposia ... partnership with the APA. ,, "It is ...
Breaking Biology Technology:Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors 2Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors 3Peoria Clinical Research Center Tests Investigational Drug to Treat Painful Menstrual Cramps 2CME Enterprise Named to Manage All Industry-Supported Symposia at 2010 APA Annual Meeting 2
... Training Center Scheduled to Open Friday, Feb. 29, ... Institute, LLC,will open its first training center in the ... local communities. Located in,Milipitas, CA, the center will be ... than 20 million Americans and costs the economy,$174 billion ...
... Continued year over year growth driven by Loestrin 24 ... Warner Chilcott,Limited (Nasdaq: WCRX ) today announced ... 2007. Revenue in the quarter ended December 31, 2007,totaled ... year quarter.,Revenue for the year ended December 31, 2007 ...
... today announced the submission of a supplemental New ... Administration (FDA) for once- daily,SEROQUEL XR(TM) (quetiapine fumarate) ... major depressive disorder (MDD) as,monotherapy, adjunct therapy, and ... 15 million American adults -- between 5 and ...
Other Biology Technology:MultiVu Video Feed: Johnson & Johnson Diabetes Institute, LLC Launches New Training Center to Improve Community-Based Diabetes Care 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 2Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 3Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 4Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 5Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 6Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 7Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 8Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 9Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 10Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 11Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 12Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 13Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 14Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 15Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 16Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007 17AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 2AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 3AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 4AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 5AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 6AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 7AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder 8
Mouse monoclonal [CIG 3A11/5] to Cig2 (rating: *****) ( Abpromise for all tested applications)....
Mouse monoclonal [3F8 ] to smooth muscle Myosin heavy chain I ( Abpromise for all tested applications). entrezGeneID: 4629 SwissProtID: P35749...
Rabbit polyclonal to CAMK 1D beta ( Abpromise for all tested applications). entrezGeneID: 57118 SwissProtID: Q5SQQ7...
Request Info...
Biology Products: